RMC-6236 to advance to Ph 3 testing in pancreatic cancer following encouraging results from a Ph 1 study
“RMC-6236 is the first targeted investigational drug designed to directly inhibit all major forms of oncogenic RAS, the major drivers of PDAC. RMC-6236 has shown compelling anti-tumor activity and a favorable safety profile in a broad population of patients with previously treated PDAC, and has potential to become an important new treatment option. Extensive efforts are ongoing toward launching RASolute 302, a global, randomized Phase 3 clinical trial comparing RMC-6236 to chemotherapy as 2L treatment of patients with metastatic PDAC.”
Share:
More News
Paul Hudson, CEO of Sanofi, commented, “The proposed acquisition of Blueprint Medicines represents a strategic step forward in our rare and immunology portfolios. It enhances our pipeline and accelerates our transformation into the world’s leading immunology company. This acquisition is fully aligned with our strategic intent to strengthen our existing
Adam Pearson, Chief Strategy Officer, Astellas commented, “Astellas is dedicated to advancing innovative therapies for some of the most challenging-to-treat cancers, such as gastric and pancreatic cancer. XNW27011 is a promising new asset that complements Astellas’ pipeline and enhances our leading position in precision oncology. We look forward to harnessing
“We were honored to present our latest research at the American Academy of Neurology Annual Meeting,” said Jay Hartenbach, President and Chief Operating Officer of Diakonos Oncology. “Glioblastoma remains one of the most aggressive and challenging cancers to treat, and we are committed to advancing novel immunotherapy approaches that have
“Patients with HER2-mutant NSCLC are predominantly women, may be of younger age and non-smokers. The FDA’s decision to grant Priority Review designation to our application for sevabertinib is a significant milestone that validates both the unmet need and the potential for sevabertinib to fulfill that need,” said Christine Roth, Executive
